# ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma

Source: https://onco.cc/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/  
OnCo record `paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Weekly paclitaxel controlled angiosarcoma in three quarters of patients at two months and produced responses in about one in five, establishing it as a standard first-line chemotherapy for this vascular sarcoma, especially of the scalp and face.

## Summary

Phase 2 study of 30 patients with unresectable angiosarcoma treated with weekly paclitaxel 80 mg per square metre.

Non-progression at two months was 74 percent, objective response 19 percent, median progression-free survival 4 months and median overall survival 8 months; responses were more frequent in scalp and face angiosarcomas.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2008
- DOI: 10.1200/JCO.2008.17.3146
- Authors: Penel N, Bui BN, Bay JO, et al.
- Findings: Non-progression rate at two months 74 percent; objective response 19 percent.; Median overall survival 8 months.
- What it means: Weekly paclitaxel is a standard first-line option for angiosarcoma alongside doxorubicin, and it is also used with radiotherapy for unresectable scalp disease.
- Caveats: Small single-arm study; survival remains poor.; The randomised ANNOUNCE and other trials have since compared taxanes with anthracyclines.

## Sources

- J Clin Oncol 2008: https://doi.org/10.1200/JCO.2008.17.3146
- PubMed: https://pubmed.ncbi.nlm.nih.gov/18809609/

## Connected records

- cancers: [Angiosarcoma](https://onco.cc/cancers/angiosarcoma/)
- trials: [ANGIOTAX](https://onco.cc/trials/angiotax/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008.json